topical product
Recently Published Documents


TOTAL DOCUMENTS

51
(FIVE YEARS 29)

H-INDEX

7
(FIVE YEARS 2)

Cosmetics ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 5
Author(s):  
Hans Stettler ◽  
Jonathan Crowther ◽  
Alison Boxshall ◽  
Stephan Bielfeldt ◽  
Bailu Lu ◽  
...  

As new biophysical methods become available to the skin researcher it is important to understand the type of information that they are capable of measuring, and how it relates to consumer perception of topical moisturizing products. The aim of the work presented here was to understand what dry skin imaging can reveal about the skin and subject feedback from the use of a topical moisturizing product and how it relates to the consumer usage experience of a topical product. Images from a dry skin camera—the Visioscan® VC 20plus—during 3 weeks in vivo usage of a topical moisturizing product were analyzed. Subject feedback regarding their skin condition was also collected. Strong statistical improvements (p < 0.05) were observed for a wide range of skin parameters derived from the Visioscan® VC 20plus. Skin scaliness and smoothness and parameters associated with skin health and appearance (surface, energy, contrast, homogeneity) improved as a result of topical product usage. Subjects reported their skin to feel less dry, to be smoother, and more supple and to look and feel healthier after product usage. The length of time until they felt the need to re-apply the product increased during the study


2021 ◽  
Vol 20 (4) ◽  
pp. 70-86
Author(s):  
I. V. Kostarev ◽  
M. A. Agapov ◽  
V. S. Groshilin ◽  
L. G. Dvaladze ◽  
D. A. Tvorogov ◽  
...  

AIM: to assess the changes in hemorrhoids symptoms and satisfaction with treatment against the background of treatment with a combined topical product Relief® Pro.PATIENTS AND METHODS: multicenter prospective non-interventional cohort study was done in 13 clinical centers in Russia. The study included patients aged 18 to 65 years with acute hemorrhoids of stages 1–2 treated with the combined product Relief® Pro (rectal suppositories, cream or a combination thereof). The follow-up period was up to 14 days (in the case of 2 visits to the clinical center after receiving the initial data). The analysis was performed on the basis of data obtained at Visit 2 (5–7 days of therapy) and Visit 3 (10–14 days of therapy) vs the initial data (Visit 1). Following criteria were used: the severity of hemorrhoid symptoms on the Sodergren scale, the severity of hemorrhoid symptoms (pain, bleeding, itching, edema, the presence of discharge, a feeling of discomfort), the size of the largest hemorrhoid node, the satisfaction of the doctor and the patient with treatment, assessment of the patient’s adherence to recommendations for lifestyle changes and treatment, evaluation of the use of the drug Relief® were evaluated as endpoints About the treatment process and patient preferences regarding the dosage form of the prescribed drug. In addition, adverse events were evaluated.RESULTS: the study included 1000 patients aged 18 to 65 years (men — 54.5%, women — 45.5%) Patients had grade 1 acute hemorrhoids (330 patients), grade 2 acute hemorrhoids (345 patients) and exacerbation of chronic hemorrhoids (325 patients). The drug Relief® Pro rectal cream was used by 333 patients; suppositories — 383 patients; joint therapy with both dosage forms — 284 patients. During follow-up (visits 2 and 3), positive dynamics was observed in patients — a decrease in the severity of hemorrhoid symptoms both during objective examination and according to patient questionnaires. So, according to the patients’ estimates, the use of Relief® Pro, regardless of the form, led to a decrease in the severity or disappearance of the main symptoms of hemorrhoids — bleeding, itching, edema, the presence of discharge, discomfort already by Visit 2 and in almost all patients by the end of observation. A similar change of the symptoms due the digital examination: by day 5–7, the severity of edema and bleeding in the perianal region, bleeding decreased. About 96% of patients and about 97% of doctors were satisfied with the treatment. Application of both forms of Relief® The ABM was characterized by good tolerability: there were no adverse events associated, according to the researcher, with the studied drug.CONCLUSIONS: combined topical product Relief® Pro is effective for hemorrhoids.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2083
Author(s):  
Francesc Navarro-Pujol ◽  
Sanja Bulut ◽  
Charlotte Hessman ◽  
Kostas Karabelas ◽  
Carles Nieto ◽  
...  

The European Medical Agency (EMA) has issued a draft guideline on the quality and equivalence of topical products. The equivalence for complex semisolid formulations involves several steps: the same quantitative content, the same microstructure, the same release, and permeation profile. In this paper, several batches of a low strength topical product, which we used as a reference/comparator product, were evaluated according to the recommendations of the EMA draft guideline. The batches were 0.025% capsaicin emulsions from the same manufacturer that were evaluated in terms of droplet size, X-ray diffraction patterns, rheology, release, and permeation profile. The generated data revealed a large batch-to-batch variability, and if the EMA guideline was applied, these batches would not be considered equivalent, although they were produced by the same manufacturer. The result of this work illustrates the difficulties in obtaining equivalence according to the current draft guidelines. It also highlights that the equivalence guidelines should consider the variability of the comparator product, and in our opinion, the guidelines should allow for claiming equivalence by comparing the limits in the variability of the data generated for the comparator product with the limits in the variability of the data generated for the intended equivalence product.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2012
Author(s):  
Tanya M. Barnes ◽  
Dalibor Mijaljica ◽  
Joshua P. Townley ◽  
Fabrizio Spada ◽  
Ian P. Harrison

Many dermatological conditions, such as eczema and psoriasis, are treated with topical therapeutic products. Instead of applying the active drug directly onto the skin, it is combined with a vehicle to aid in its delivery across the stratum corneum (SC) and into deeper regions of the skin, namely the epidermis and dermis. Absorption into the systemic circulation is minimized. Topical vehicles are also used as cosmetic moisturizers (often termed emollient therapy) to ameliorate dry skin, which is a cornerstone of the management of various dermatological conditions, including xerosis, eczema, psoriasis, and aging. The most common topical vehicles include ointments, creams, gels, and lotions, among others. It is crucial that topical vehicles are chosen based upon the size and properties (wet/dry, mucous/non-mucous, healthy/diseased) of the skin to be treated in order to optimize application and contact of the product with the skin, as this can have profound impacts on potency, efficacy, and patient compliance. This review examines common topical vehicles used for drug delivery and cosmetic moisturizers, including their formulation, advantages and disadvantages, and effects on the skin. The unique rules imposed by governing regulatory bodies in Australia and around the world, in terms of topical product claims, are also briefly examined.


2021 ◽  
Vol 15 (1) ◽  
pp. 125-137
Author(s):  
Robert LeBlanc ◽  
Sohan De Silva ◽  
Martin Terry

The purpose of this study was to investigate samples of commercial over-the-counter products purported to contain extracts from peyote cactus (Lophophora williamsii), a vulnerable species. Samples were extracted with organic solvent and then washed to remove impurities. The extracts of these products were subjected to an analysis by real-time mass spectrometry (DART-MS) to determine the presence or absence of the alkaloid mescaline (3,4,5-trimethoxyphenethylamine). High-performance liquid chromatography (HPLC) was used to determine mescaline concentrations in the samples and to provide quantitative evidence of the concentration—if any—of mescaline in the products. If a detectable level of mescaline—a stable and abundant alkaloid of L. williamsii—was found in a given extract, then it was inferred that L. williamsii was present in the corresponding topical product. The results of this investigation show that most consumers who purchase the products in question are being defrauded if they believe they are buying L. williamsii-based medicines. The lack of mescaline—implying the lack of peyote—in these products suggests that wild populations of the vulnerable cactus L. williamsii, though currently being decimated on a massive scale in Mexico and the U.S. for other purposes, are rarely harvested for use in topical analgesic products. This conclusion is based on the finding that less than 5% of the ostensible L. williamsii-containing topical analgesic products that were analyzed in this study actually contained mescaline.


Author(s):  
Sachin M Shridharani

Abstract Background Optimizing post procedural recovery and outcomes for patients is the aim for all physicians. TransFORM Body Treatment with TriHex Technology (TFB) is a topical product that aids in the elimination of fat particles created during procedures and the reduction of associated inflammation, thus, speeding up post procedure recovery time. Objectives Evaluation of post procedural symptoms, signs and healing following submental deoxycholic acid (DCA) injections in combination with TFB post treatment. Methods Participants received two treatments of submental DCA injections. Post treatment 1 every participant received TFB to apply twice daily to the submental area. Follow-up visits included weeks 1, 2 and 4. After week 4, participants discontinued TFB for 30 days prior to the second treatment. At the second treatment visit, participants were randomized to receive either TFB or a bland moisturizer to apply twice daily with the same follow-up visits as post treatment one. Skinfibrometer measurements (objective induration measurements), submental fullness grading and standardized photography were captured at every visit. At all follow-up visits and prior to treatment 2, investigator assessments and participant assessments were completed. Results Post treatment two, investigator assessments of edema and induration decreased in participants using TFB at weeks 1 and 2 compared to the bland moisturizer. Skinfibrometer measurements objectively showed a statistically significant reduction in induration at week 2 (post treatment two) in participants using TFB compared to the bland moisturizer. Furthermore, participants reported less tenderness and soreness in the TFB group over the bland moisturizer. Conclusions Investigator assessments, participant query and objective skinfibrometer analyses have demonstrated that the use of TFB post DCA injections may reduce induration, edema and discomfort associated with this procedure.


2021 ◽  
Vol 06 (04) ◽  
pp. 1-1
Author(s):  
Scarlett Puebla-Barragan ◽  
◽  
Britney Lamb ◽  
Serenah Jafelice ◽  
Gregor Reid ◽  
...  

Vaginal care products are widely used by women to relieve discomfort such as pain, itching and malodour, all of which are commonly caused by conditions resulting from microbiota dysbiosis. Previous studies showed that probiotic strains Lacticaseibacillus (formerly Lactobacillus) rhamnosus GR-1 (LGR-1) and Limosilactobacillus (formerly Lactobacillus) reuteri RC-14 (LRC-14), can aid in restoring homeostasis in the vaginal microbiome when taken orally. A topical product containing these strains could be of value for reducing malodour and improving quality of life. However, the formulation of such a product is a challenge, given that its ingredients must maintain shelf-life viability by excluding moisture. Here, we tested petroleum jelly, mineral oil, coconut oil, and olive oil for how well they maintained the viability of freeze-dried probiotic strains over a six-month timeframe. None of the oils caused excessive loss of bacterial viability, with petroleum jelly and coconut oil showing the most promise. Based on existing knowledge of these oils on the female genitalia, coconut oil and petroleum jelly could be suitable probiotic carriers for clinical testing.


2021 ◽  
Vol 49 (03) ◽  
pp. 210-214
Author(s):  
Teresa M. S. A. Boehm ◽  
Christoph J. Klinger ◽  
Christine Gohl ◽  
Maike Lücht ◽  
Katja N. Baumann ◽  
...  

AbstractA 30-year-old, intact female Indian rhinoceros (Rhinocerus unicornis) was presented with ongoing erosive, ulcerative skin lesions over a 4-year-period. The lesions appeared to be non-pruritic and non-seasonal. A systemic antibiotic therapy had been unsuccessful. The dermatological examination showed 8 diffusely demarcated areas of erosion, focal ulceration, mild crusting, and moderate erythema ranging from 8 to 20 cm in diameter, bilaterally on the lateral edges of the torso armor plates. The patient had no other clinical abnormalities. Coccoid and rod-shaped bacteria were identified on cytology and a bacterial culture revealed Escherichia coli spp., Staphylococcus dysgalacticae, Stenotrophomonas maltophilia, Corynebacterium spp. and Micrococus spp. A topical product line containing essential fatty acids and plant extracts was administered daily, using a spot-on, spray and balm. Within 3 weeks a substantial alleviation of clinical signs was observed. Multiple impression smears of the lesions and a bacterial culture were negative by day 21. The patient achieved complete remission within 4 months of treatment and maintained remission for the 2-year observation period with continued use of the medication. Topically administered therapeutics containing essential fatty acids and plant extracts may offer a viable treatment option for recurrent cases of bacterial infectious skin lesions in Indian rhinocerotidae.


Sign in / Sign up

Export Citation Format

Share Document